HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and increased the price target from $6 to $7.
March 11, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reaffirmed its Buy rating on Aquestive Therapeutics and raised the price target from $6 to $7.
The upgrade in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100